NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.5307
-0.0174 (-3.17%)
At close: 4:00PM EDT

0.5300 -0.00 (-0.13%)
Pre-Market: 8:46AM EDT

Stock chart is not supported by your current browser
Previous Close0.5481
Open0.5399
Bid0.5200 x 4000
Ask0.5800 x 800
Day's Range0.5201 - 0.5480
52 Week Range0.4900 - 2.5800
Volume12,109,706
Avg. Volume16,926,654
Market Cap249.139M
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga2 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Novavax faces delisting threat following failed drug trial
    American City Business Journals3 days ago

    Novavax faces delisting threat following failed drug trial

    Nasdaq has warned Novavax Inc. that its stock could be delisted if it can’t get the price consistently above a buck within the next six months. The Gaithersburg biotech’s stock has fallen below $1 for 30 consecutive days and the company has 180 days — until Oct. 8 — to regain compliance by getting its common stock bid price up for at least 10 consecutive business days. Novavax plans to hold a special stockholder meeting May 8 to consider a reverse stock split, according to public filings.

  • Benzinga5 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • Novavax (NVAX) Stock Moves -0.67%: What You Should Know
    Zacks7 days ago

    Novavax (NVAX) Stock Moves -0.67%: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.57, marking a -0.67% move from the previous day.

  • Thomson Reuters StreetEvents13 days ago

    Edited Transcript of NVAX earnings conference call or presentation 18-Mar-19 8:30pm GMT

    Q4 2018 Novavax Inc Earnings Call

  • Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
    Zacks13 days ago

    Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.59, marking a +1.57% move from the previous day.

  • Novavax (NVAX) Gains As Market Dips: What You Should Know
    Zacks22 days ago

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    In the latest trading session, Novavax (NVAX) closed at $0.53, marking a +0.21% move from the previous day.

  • 3 Cheap Stocks to Buy That Are Worth Every Penny
    InvestorPlace27 days ago

    3 Cheap Stocks to Buy That Are Worth Every Penny

    So close, and yet so far. That sums up the state of the markets recently, with investors jittery over the sudden chill surrounding U.S.-China relations. In an about-face on the trade dispute, President Trump conceded that tariffs on Chinese goods may remain for a "substantial period of time." Simultaneously, this hurts the broader markets but it also raises prospects for cheap stocks.I know what you're thinking: why should I consider cheap stocks to buy when blue-chip names are also available for deeply discounted prices? Far be it from me to disagree with that logic. Typically, you accrue the biggest profits from striking while others are panicking. But after you're comfortable with your high-probability bets, penny stocks provide exceptionally robust return potential.We should also discuss the "under-the-radar" argument. News such as the trade-war dispute disproportionately hurt the blue chips because they're usually multinational corporations with global vulnerabilities. While penny stocks also suffer the trickle-down effect, they're more likely to move on sector-specific developments.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best ETFs to Buy in the Second Quarter With that in mind, let's take a look at three (very) cheap stocks to buy that are worth every penny: Entree Resources (EGI)Source: Jeremy Vohwinkle via Flickr (Modified)Entree Resources (NYSEAMERICAN:EGI) is one of the penny stocks that actually benefits from broader and sector-specific trends. With all eyes focused on the suddenly deteriorating trade-war dispute, investors get nervous. When investors get nervous, they buy gold. Naturally, as a gold miner, EGI has a lot to gain.Another thing that intrigued me about EGI as a candidate for cheap stocks to buy is its locality. Most speculative miners have projects in extremely unstable countries just begging for nationalization. While Entree's main property in Mongolia isn't the greatest region for stability, it's also not the worst. Over the last few years, Mongolia improved its standing for ease of doing business.Additionally, the gold price has also improved, gaining roughly 10% since the first of October. That's a net positive for EGI stock, especially since it might go higher still. However, keep in mind that gold is extremely volatile, so don't lever yourself excessively. Genius Brands International (GNUS)Source: Shutterstock The entertainment industry is a tough sector in which to survive, let alone thrive. What works and what doesn't often seem arbitrary. Moreover, maintaining relevance is a gargantuan task once you've accomplished the already difficult task of delivering a hit. But the prospect of finding that hit drives Genius Brands International (NASDAQ:GNUS).GNUS specializes in creating compelling content and characters. Where it differs compared to other cheap stocks in the entertainment field is the company's core audience: toddlers to tweens. This is an exceptionally challenging market to crack because you're dealing with two audiences: the young consumer and their parents/guardians. * 10 Stocks on the Rise Heading Into the Second Quarter At the same time, GNUS has a viable pathway to profound growth. The reason? Brands such as cartoon characters translate very well internationally. If it resonates in America, it will probably resonate everywhere else. Novavax (NVAX)Source: Shutterstock Over the past few years, vaccination captured the public's attention, and not always in a good way. With President Trump's election, an increasing number of people became aware of so-called alternative-truth movements. Many of these right-leaning organizations rally fiercely against vaccination, particularly government-imposed protocols.On the surface, that doesn't help Novavax (NASDAQ:NVAX), which specializes in the stuff. Nor does the fact that NVAX is one of the riskiest penny stocks to buy. Since Feb. 27, shares have plummeted nearly 71%. Even more concerning is the reason why NVAX fell.In a clinical trial, the company's NanoFlu treatment failed to beat placebo. In other words, positive thinking yielded roughly the same efficacy in preventing influenza than the vaccine.Given that NVAX is a fundamentally poor organization, I'm not surprised that shares fell. However, keep in mind that most Americans support vaccination. Therefore, the broader financial incentive to stay the course until efficacy improves is incredibly high.As of this writing, Josh Enomoto is long gold. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post 3 Cheap Stocks to Buy That Are Worth Every Penny appeared first on InvestorPlace.

  • Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
    Zacks27 days ago

    Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

    Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

  • Why Novavax Is Soaring Today
    Motley Fool29 days ago

    Why Novavax Is Soaring Today

    Investors' optimism about the prospects for the biotech's experimental vaccines appears to be increasing.

  • Does Novavax Have a Viable Path Forward?
    Motley Fool29 days ago

    Does Novavax Have a Viable Path Forward?

    Novavax needs a deep-pocketed partner soon.

  • What's Next for Novavax?
    Motley Fool29 days ago

    What's Next for Novavax?

    The beleaguered biotech is down but not out.

  • Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript

    NVAX earnings call for the period ending December 31, 2018.

  • Associated Presslast month

    Novavax: 4Q Earnings Snapshot

    The Gaithersburg, Maryland-based company said it had a loss of 13 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...

  • Is a Beat in Store for Catabasis (CATB) This Earnings Season?
    Zackslast month

    Is a Beat in Store for Catabasis (CATB) This Earnings Season?

    Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

  • Why Novavax Stock Imploded in February
    Motley Foollast month

    Why Novavax Stock Imploded in February

    Novavax's latest clinical failure may prove to difficult to overcome.

  • What's in the Cards for Novavax (NVAX) This Earnings Season?
    Zackslast month

    What's in the Cards for Novavax (NVAX) This Earnings Season?

    Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

  • What another failed drug trial means for Novavax’s future
    American City Business Journalslast month

    What another failed drug trial means for Novavax’s future

    Novavax remains optimistic about the findings of the study. Analysts and investors aren't so sure.

  • TheStreet.comlast month

    Take a Poker Player's Approach to Playing Small Biotech Stocks

    As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.

  • The 3 Oldest Members of Biotech's Billion-Burned Club
    Motley Fool2 months ago

    The 3 Oldest Members of Biotech's Billion-Burned Club

    These biopharmaceutical startups have been losing their investors' money for decades.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...

  • Can Novavax Convince the FDA Its Vaccine Deserves a Chance?
    Motley Fool2 months ago

    Can Novavax Convince the FDA Its Vaccine Deserves a Chance?

    Despite a second pivotal trial failure, this beaten-down biotech isn't giving up on its lead candidate.

  • Why HP, Booking Holdings, and Novavax Slumped Today
    Motley Fool2 months ago

    Why HP, Booking Holdings, and Novavax Slumped Today

    Find out about the bad news these stocks suffered.

  • Why Novavax Is Tanking Today
    Market Realist2 months ago

    Why Novavax Is Tanking Today

    Why Novavax Is Tanking TodayShare price movementsToday, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price. The company has a market capitalization of $806.95 million.Today, the company issued a